FDA to Implement AI Across All Centers by June 30

The U.S. Food and Drug Administration (FDA) has announced that it will begin deploying artificial intelligence (AI) across all its centers immediately, with full integration set for June 30, 2025. This move follows the successful completion of a pilot program that used generative AI to assist scientific reviewers.

The integration of AI is aimed at streamlining the drug review process, reducing time-consuming tasks, and increasing efficiency. The FDA’s goal is to enhance its ability to assess and approve drugs faster, ensuring better outcomes for patients while maintaining high regulatory standards.

Jeremy Walsh, the FDA’s Chief AI Officer, will oversee the rollout, which involves unifying the agency’s AI systems to improve workflow, security, and usability. With this new AI-driven approach, tasks that once took days can now be completed in minutes, speeding up the overall review process.

As the initiative progresses, the FDA plans to refine its AI tools based on user feedback and will continue to provide updates on its development.